Received: from DB8P191CA0014.EURP191.PROD.OUTLOOK.COM (2603:10a6:10:130::24) by AS2PR02MB9486.eurprd02.prod.outlook.com (2603:10a6:20b:59a::6) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.428.16; Sun, 20 Sep 2026 15:21:05 +0000 Received: from AS2PR02MB9486.eurprd02.prod.outlook.com (2603:10a6:20b:59a::6) by VI1PR02MB5760.eurprd02.prod.outlook.com with HTTPS; Sun, 20 Sep 2026 15:21:07 +0000 Received: from mail1.rit.ee (213.184.53.4) by DB5PEPF00014B90.mail.protection.outlook.com (10.167.8.228) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.451.8 via Frontend Transport; Sun, 20 Sep 2026 15:21:04 +0000 Received: from DB5PEPF00014B90.eurprd02.prod.outlook.com (2603:10a6:10:130:cafe::6b) by DB8P191CA0014.outlook.office365.com (2603:10a6:10:130::24) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.428.16 via Frontend Transport; Sun, 20 Sep 2026 15:21:05 +0000 Reply-To: "Terviseamet" From: "Terviseamet" To: "Info - TA" Subject: =?utf-8?Q?Veebivormi_edastus:_P=C3=B6=C3=B6rdumise_v?= =?utf-8?Q?orm?= Date: Sun, 20 Sep 2026 18:21:03 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0092_01DD499F.B12B1000" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQJkzRhbndrR8zgodGE1KO/rC+ahZg== Authentication-Results: spf=fail (sender IP is 213.184.53.4) smtp.mailfrom=vportal.ee; dkim=pass (signature was verified) header.d=vportal.ee;dmarc=pass action=none header.from=vportal.ee;compauth=pass reason=100 X-CSE-ConnectionGUID: S7cV/HQKSS29TRaprbW0RA== X-CSE-ConnectionGUID: AFcXzkLCSVSl+ogx8dBqpQ== X-CSE-MsgGUID: FaJrAZzWRySRRQ07/Rrxdg== X-CSE-MsgGUID: +C8h1qdaTSaui6tHyYJv/g== X-IronPort-AV: E=Sophos;i="6.27,112,1787000400"; d="scan'208,217";a="80493212" X-Amp-Result: SKIPPED(no attachment in message) X-Amp-File-Uploaded: False X-MS-Exchange-Organization-ExpirationStartTime: 20 Sep 2026 15:21:04.4050 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 94365eeb-f8f7-4213-7fc3-08df172ac959 X-EOPAttributedMessage: 0 X-EOPTenantAttributedMessage: 8fe098d2-428d-4bd4-9803-7195fe96f0e2:0 X-MS-Exchange-Organization-MessageDirectionality: Incoming X-MS-PublicTrafficType: Email X-MS-TrafficTypeDiagnostic: DB5PEPF00014B90:EE_|AS2PR02MB9486:EE_|VI1PR02MB5760:EE_ X-MS-Exchange-Organization-AuthSource: DB5PEPF00014B90.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Anonymous X-MS-Office365-Filtering-Correlation-Id: 94365eeb-f8f7-4213-7fc3-08df172ac959 X-MS-Exchange-AtpMessageProperties: SA|SL X-MS-Exchange-Organization-SCL: -1 X-Microsoft-Antispam: BCL:0;ARA:13230040|82310400026|260918224100599003|260918215300599003|10067099003|5063699009|6143699003|19002099009|18002099003|16102099003|55112099003|57112099003|11063799006|8096899003; X-Forefront-Antispam-Report: CIP:213.184.53.4;CTRY:EE;LANG:et;SCL:-1;SRV:;IPV:CAL;SFV:NSPM;H:mail1.rit.ee;PTR:mail1.rit.ee;CAT:NONE;SFS:(13230040)(82310400026)(260918224100599003)(260918215300599003)(10067099003)(5063699009)(6143699003)(19002099009)(18002099003)(16102099003)(55112099003)(57112099003)(11063799006)(8096899003);DIR:INB; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 20 Sep 2026 15:21:04.1948 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 94365eeb-f8f7-4213-7fc3-08df172ac959 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: DB5PEPF00014B90.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Anonymous X-MS-Exchange-CrossTenant-FromEntityHeader: Internet X-MS-Exchange-Transport-CrossTenantHeadersStamped: AS2PR02MB9486 X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.6315050 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0428.008 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: =?us-ascii?Q?EjYGoYerIK88e5IHRfWe4sN5kBA/ftwwpkiVGWRyDowtilELoKIlEGGzEfYh?= =?us-ascii?Q?ZUdoPlljiBF3EGBu++NcO94uz5Rg9/OF7/dzyhuv/r5eommC9n2QfZ/C5vVM?= =?us-ascii?Q?0VcaRit0B/VHIptuh2lfLjuRccYZ79On+nkQCJXUkJRBUUStoKES8b52MrFz?= =?us-ascii?Q?FPttrTfvKp3nUvZIE36jGvd3R21rjrZOIKJGosgRa88MLzH0g9RRtaRukHQc?= =?us-ascii?Q?qlAFjmUx9Y7nSXgRGlcZ8J1sQaIgLhceMljAanjl0Esrp20TO/3hv5007aec?= =?us-ascii?Q?2wjbSiUIp8ZAI6oCE070YJEeiatgOD1IqODNnN5B5QLiFBfv6pQfOZdHNXxT?= =?us-ascii?Q?kmChWS/iRKT81QUlBQADj+OvI00iqFzZ0f3rgKO/7QopX4hPlbwAQ2l+c1TX?= =?us-ascii?Q?Eu+oFvGmIeO6IMfTs275ecmR7mC5n+JhxA95mKzS26RxzplTIsE+UIDozsrl?= =?us-ascii?Q?Kvn7qwUrSqL0j0HVYcA0JNGkkMRx7Z9gtWW46px0EQTQGfLWn2qMKHJR/dKh?= =?us-ascii?Q?9RA+ddMGbci+VQwWJneK4KvUoFDh5wtTAQ294WmqMC5w/9Gg4MX0CqxhjnjO?= =?us-ascii?Q?SGG6PTk7KEYiu4cr+sZAeAK2X9kPnSCg99AA9I3zCzZvNqdxKtVotIW8cj59?= =?us-ascii?Q?4WtuL9DSQ+NZIkssFMNHIjLdNDoQEO6GCjdp1RbCq959INkSYLmrJAb96KBw?= =?us-ascii?Q?NBKWaiE0pha8tJXkdiYp/6MfySLr6CQPBrx4ByO/35gdkPGc5nl nq7ec8oSO?= =?us-ascii?Q?2seG64yNVXlYTrMTmhvd7DzjkwlPytu5DuN4vS4AfiERj8YuF2ynqtovvBCP?= =?us-ascii?Q?LenPgzcZoyxMueNcZxmOuKmsfO1ueGxn/mGQaJUdSOOOQuWsf5Xu46ixYKMO?= =?us-ascii?Q?sOdayd/vOOj7xfmlSiqfW1HvgD0HDX65UKuaf31sToZArlz9OoSFXwzSUOgi?= =?us-ascii?Q?wJ1v7w+GHw9JmAD0xqB0sXkDFkbNfJFXpGVFjzmvvIRXfQ0b5vZBVV2ddvVm?= =?us-ascii?Q?CSPARPUfKfiN6gIzxVO9MuuItGuLbIMcCDpxFPF7WQ8zZisFCEdK/6ofSay8?= =?us-ascii?Q?Q1dcQPQucx0NPZ2f9XRT4s2oBGTzoVvTKoxJSjnA/4K6MGxvokHEXCwqJU1o?= =?us-ascii?Q?eo23gqA7i/wxBAMMfnEqyBzak5EQIkilEtWO4n1rCY8d+NznSyklBIqvgj0b?= =?us-ascii?Q?s4TJxNb0o5Dpx9FP0WZXpAFzVGubmlCipBMi65g3IbdPT/cV63MCBvmJXasA?= =?us-ascii?Q?4WbsBBaTeDf9TYEWzrAblbGWUfAgbRUDhFDheDZreazi0B0lulcMXyiTmauF?= =?us-ascii?Q?Ni4S3/k3vseL6u+VCunUMAxYSdcbHuU8EstKrV04i6pnmF1i1ulEWZOtXlfe?= =?us-ascii?Q?s1rqikvuvaIdqdX+sQhU2Ow0U2AZnJPUy8SyzEahAL/doXGrhZ/38T+55tTZ?= =?us-ascii?Q?vm1IrpAisDo/wzPaR/fpQtq3f8N/rpJX2LM+uZxtZsNRmDHKC5LsQrCDHGzX?= =?us-ascii?Q?YUiXuD8FswfpuVaxIRMC9869s6zvvDWq6Mbyo lcwYroRcScTfnIHljNmkrWG?= =?us-ascii?Q?7KAxs45asCiUpGryoiej65iJ7ijHHThO15UC6DfbJwVkNqIBg5aIuqrux4gn?= =?us-ascii?Q?c0jLxCRXiJh/udNMf7RaU4gU9FIKM7/Q+QcJtOvAxp4LJIWdfVHMWSo7FWe8?= =?us-ascii?Q?kHys2jZ4CcxZbrTg0krclvIl+nb7V9+a/kSdJN0yJideNLzOGXBDEzI92/Px?= =?us-ascii?Q?45CYldrd3fq8Ozw4KWuooVt4TGu5r7bQB06SzubVWiiCltLcst35nNmNAdSQ?= =?us-ascii?Q?XCl9gHwcADnhwE5ODdu54WQZ4qT+RkR10H4hCcWUwMJCubj5ZzVdDD3rsqjd?= =?us-ascii?Q?qmf0LX2bFGrzDUtjb/uM3Yt2X926+B5jLL6a8dO/zuBZqPiE9NIaJU+s8NSc?= =?us-ascii?Q?/y0MVZUI529I9tO4xdHshXV9Wc5WS+4S7JYtSrI9IVY/OuscZKHbxYaJwKEN?= =?us-ascii?Q?1hadEtmHpqIEXtogi05MAjS2jqhgr/Ovl9vWhi0mhnX7k2jPA5c8g+BEOTWu?= =?us-ascii?Q?3yRE8kFsSChv3D9yTuXLRE5+f2gNgsAz4Lz1wjJvXLhHAMdmL0WKiRcqLdXX?= =?us-ascii?Q?Xp95gUPpUp95mgsUOPI7jc0zOESrfJ3wJabIf89i0y5PLnJzcXXr4bZoUDgF?= =?us-ascii?Q?cdIChA6pHDqpzayQcs1uphtWcEaXwTNveFmHMHYvuOxoYvbf0VR5iPnewUad?= =?us-ascii?Q?ktmDyiHypUETqFikWPZ1ifcTz+m2Mq3rjh2Zdpchy4jFKeF4xh9I61OOdiFt?= =?us-ascii?Q?0ioLcKckqJlk+nyWEzF2aUU JX7XkHXu6o2qP3DmtlIQeSVdKD6UmZPkKNBZV?= =?us-ascii?Q?eJ1kGJIk93THpL2fpcViemTxufVOOuZFNtblV3yRC9ydmysoh/yAbLDrBRHn?= =?us-ascii?Q?nWxc4u5x8foMaruqB6udJngvA9iVWnwAQy4RIKogah8kSJosu/5AUG+QLhQB?= =?us-ascii?Q?T1UqMkZyp5Yze9UkTxfTBMvBLG8ID+ztawoAif68JbuwT0hwV/I3CJyiiVTk?= =?us-ascii?Q?6Aa/h3xgm3EuBinWyeO83hm7hv+hYsYIm8RhL7FxxUwOzM3kcPowh3qgjGGS?= =?us-ascii?Q?KMs5yAB/2AgqBhbTFiQlFCAyB7Goqd3mkU/J4/iKKLpg?= Content-Language: et x-ms-exchange-organization-originalclientipaddress: 213.184.53.4 x-ms-exchange-organization-originalserveripaddress: 10.167.8.228 dkim-signature: v=1; a=rsa-sha256; c=relaxed/simple; d=vportal.ee; s=mail; h=sender:subject:from:reply-to:to:message-id:date; bh=in826mqrzTzCY6yz8esW56FcZ7I9AMaQk2JIqBXNaaM=; b=BYjGKxTO2ohPmqynJGYGLfhFfZaVLno+fwU13Ii4Qhkz3EzZI9FtxqnH 9pUcZnWpDWXstkeWHAyIhM2+2oE5i3YP8pdi8hts4TU/MhuFECGqxJod5 MlIU/eGkYKH2teYB0JoTgcfmJc7dFeEDGRrGsUmPm8soPw2cHpxtzHYib a6YdfiucOmN73ZsYaicrHfJJDDK+6PcTM/Xm4KhNBPxV82ANXMUciqQxt ytqnszcJPrOx9tgvMGbd7Ij2EzNksd6tbZCO33TLhnxKDZAWOU1TTwdyH EfwR8jbpAcFUocHeV+OIurBpFVPCQ7hOU2VYVdOng4JWWzeacS3fQfnuG g==; received-spf: None (mail1.rit.ee: no sender authenticity information available from domain of postmaster@mailgw12.rmit.ee) identity=helo; client-ip=195.80.115.29; receiver=mail1.rit.ee; envelope-from="terviseamet_noreply@vportal.ee"; x-sender="postmaster@mailgw12.rmit.ee"; x-conformance=spf_only X-OlkEid: 00000000C2F100042791FD488835E929BC7E6508070034AD76187591974DBF6C4F76951C873A0100020000000000FEAC6C021EAD0E46B13124BDE57E2D4F000000002EAC0000AE649D148A5FD046991AD2EA96199ED4 This is a multipart message in MIME format. ------=_NextPart_000_0092_01DD499F.B12B1000 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Sisestuse kuupäev P, 20/09/2026 - 18:17 Sisestaja: vportal_rest Sisestatud veebivormi info: Ees- ja perekonnanimi Margus Šuman Asutuse nimetus / Juriidilise isiku nimi Nocta OÜ E-posti aadress noctaitinfo@gmail.com Pöördumise tüüp Selgitustaotlus Pöördumise valdkond Nakkushaiguste epidemioloogia PÖÖRDUMISE SISU (kuni 2000 tähemärki) Tere, Arendame tervishoiu SaaS-lahendust ja soovime mõista NAKIS (nakkushaiguste infosüsteem) nõudeid tarkvaratootjale/raviasutusele: 1. Milline on NAKIS-esse teatamise kohustuse täpne õiguslik alus? 2. Milline asutus/süsteemi omanik vastutab tehnilise liidestumise eest? 3. Millised on eraldi TEST- ja TOODANG-keskkonna onboardingu protsessid? 4. Millised on liidestumise/kasutamisega seotud kulud/tasud? 5. Kas NAKIS on eraldiseisev liides, või toimub teatamine TIS-i kaudu? 6. Millistele raviasutustele/töövoogudele on NAKIS-esse teatamine seaduse järgi kohustuslik? Lugupidamisega, Margus Šuman Nocta OÜ Vastust soovin e-posti teel ------=_NextPart_000_0092_01DD499F.B12B1000 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
=20

Sisestuse kuup=C3=A4ev = P, 20/09/2026 - 18:17

Sisestaja: vportal_rest

Sisestatud veebivormi info:

Ees- ja perekonnanimi
Margus =C5=A0uman

Asutuse nimetus = / Juriidilise isiku nimi
Nocta = O=C3=9C

E-posti = aadress
noctaitinfo@gmail.com

P=C3=B6=C3=B6rdumise t=C3=BC=C3=BCp
Selgitustaotlus

P=C3=B6=C3=B6rdumise valdkond
Nakkushaiguste epidemioloogia

P=C3=96=C3=96RDUMISE SISU (kuni 2000 t=C3=A4hem=C3=A4rki)
Tere,

Arendame tervishoiu SaaS-lahendust ja soovime m=C3=B5ista NAKIS = (nakkushaiguste infos=C3=BCsteem) n=C3=B5udeid = tarkvaratootjale/raviasutusele:
1. Milline on NAKIS-esse teatamise kohustuse t=C3=A4pne =C3=B5iguslik = alus?
2. Milline asutus/s=C3=BCsteemi omanik vastutab tehnilise liidestumise = eest?
3. Millised on eraldi TEST- ja TOODANG-keskkonna onboardingu = protsessid?
4. Millised on liidestumise/kasutamisega seotud kulud/tasud?
5. Kas NAKIS on eraldiseisev liides, v=C3=B5i toimub teatamine TIS-i = kaudu?
6. Millistele raviasutustele/t=C3=B6=C3=B6voogudele on NAKIS-esse = teatamine seaduse j=C3=A4rgi kohustuslik?

Lugupidamisega,
Margus =C5=A0uman
Nocta O=C3=9C

Vastust = soovin
e-posti teel
------=_NextPart_000_0092_01DD499F.B12B1000--